PT - JOURNAL ARTICLE AU - Emmi, Aron AU - Sandre, Michele AU - Russo, Francesco Paolo AU - Tombesi, Giulia AU - Garrì, Federica AU - Campagnolo, Marta AU - Carecchio, Miryam AU - Biundo, Roberta AU - Spolverato, Gaya AU - Macchi, Veronica AU - Savarino, Edoardo AU - Farinati, Fabio AU - Parchi, Piero AU - Porzionato, Andrea AU - Bubacco, Luigi AU - De Caro, Raffaele AU - Kovacs, Gabor G AU - Antonini, Angelo TI - Duodenal alpha-Synuclein pathology and enteric gliosis in advanced Parkinson’s Disease patients AID - 10.1101/2022.06.16.22276347 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.16.22276347 4099 - http://medrxiv.org/content/early/2022/06/22/2022.06.16.22276347.short 4100 - http://medrxiv.org/content/early/2022/06/22/2022.06.16.22276347.full AB - Background The role of the gut-brain axis has been recently highlighted as a major contributor to Parkinson’s Disease (PD) physiopathology, with numerous studies investigating bidirectional transmission of pathological protein aggregates, such as α-Synuclein (αSyn), in the context of neurodegenerative disease. However, little and often conflictual evidence is available from human studies due to patient heterogeneity, sampling variability, and the employment of antibodies with affinity for different αSyn epitopes.Objectives We aimed to investigate the enteric nervous system (ENS) in PD by characterizing αSyn alterations and glial responses in duodenum biopsies of PD patients by employing topography-specific sampling and conformation-specific αSyn antibodies.Methods 18 Patients with symptomatic PD who underwent Duodopa Percutaneous Endoscopic Gastrostomy and Jejunal Tube (PEG-J) procedure, as well as 18 age- and -sex-matched Healthy Control subjects undergoing routine diagnostic endoscopy, were included in the study. A mean of 4 duodenal wall biopsies were sampled from each patient. Immunohistochemistry was performed for anti-aggregated αSyn (5G4) and GFAP antibodies. Morphometrical-semi-quantitative analysis was performed to characterize αSyn-5G4+ and GFAP+ density and size.Results Elevated immunoreactivity for aggregated α-Syn was identified in all biopsies of PD patients compared to controls. αSyn-5G4+ colocalized with neuronal marker β-III-tubulin. Evaluation of enteric glia cells revealed an increased size and density when compared with controls, suggesting reactive gliosis.Conclusions Duodenal biopsy may represent a feasible and reliable tool for characterizing PD pathology in the GI tract and discerning patients from controls. Future studies are required to confirm these findings in a prodromal or early PD phase.Competing Interest StatementAA has received compensation for consultancy and speaker related activities from UCB, Boehringer Ingelheim, Ever Pharma, General Electric, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Theravance Biopharma, Jazz Pharmaceuticals, Roche, Medscape; he receives research support from Bial, Lundbeck, Roche, Angelini Pharmaceuticals, Horizon 2020: Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081, Cariparo Foundation, Movement Disorders Society for NMS Scale validation. He serves as consultant for Boehringer-Ingelheim for legal cases on pathological gambling. GGK has served as an advisor for Biogen; received royalty for 5G4 synuclein antibody and publishing royalties from Wiley, Cambridge University Press and Elsevier, received grants from Edmond J Safra Philanthropic Foundation, Rossy Foundation, Michael J. Fox Foundation, Parkinson Canada, Canada, and Canada Foundation for Innovation.Funding StatementThe project was supported by 'Segala award' from SIN and Limpe to MiC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol received approval by the ethical committee for clinical experimentation of Padua Province (Prot. n. 0034435, 08/06/2020). Informed consent for the use of biological samples was obtained from all patients. All procedures on human tissue samples were carried out in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors